<DOC>
	<DOCNO>NCT01148134</DOCNO>
	<brief_summary>This study characterize pharmacokinetics vincristine use two different cohort patient . The first cohort include patient acute lymphoblastic leukemia ( ALL ) Bcr-Abl positive . This cohort patient receive vincristine along imatinib induction chemotherapy regimen . The second cohort include patient ALL Bcr-Abl negative . This cohort patient receive vincristine without imatinib induction chemotherapy regimen . This study involve blood draw begin day 7 treatment protocol sample analyze pharmacokinetic parameter . Imatinib vincristine metabolize hepatic CYP 450 enzyme system . Imatinib inhibitor system co-administration imatinib vincristine potential increase blood level vincristine . This could explain increased level neurotoxicity currently see co-administration two agent treatment Bcr-Abl positive ALL .</brief_summary>
	<brief_title>Pharmacokinetic Profile Vincristine Administered With Imatinib Bcr-Abl Positive Acute Lymphoblastic Leukemia ( ALL ) Compared That Without Imatinib Bcr-Abl Negative ALL</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Age &gt; /= 18 year New Diagnosis BcrAbl positive ALL BcrAbl negative ALL Receiving induction chemotherapy standard Princess Margaret Hospital modify DFCI protocol Will function central venous access catheter insitu Agreeing participate study sign inform consent form Concomitant use agent inhibit hepatic cytochrome CYP3A4 , drug may alter vincristine imatinib level Elevated liver function test : bilirubin &gt; 1.5xULN AST/ALT &gt; 2.5xULN , document history chronic liver disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>